Establishment and characterization of a new human erythroleukemic cell line, ERY-1.
The growth factor-independent erythroleukemic cell line ERY-1 was established from the peripheral blood of a 87-year-old woman with chronic myeloid leukemia (CML) in the acute phase. Immunophenotyping showed that fresh leukemic cells were positive for CD13, CD33, CD36 and CD235a (glycophorin A), a phenotype compatible with that of erythroblastic cells. Cytogenetic and fluorescence in situ hybridization (FISH) analysis demonstrated classical t(9;22)(q34;q11) chromosomic translocation associated with a duplication of the BCR-ABL fusion gene. Other cytogenetic abnormalities were detected in all analyzed mitosis, the most frequent being a trisomy of chromosome 8. The established ERY-1 cell line retains these immunophenotypic and cytogenetic features, and light and electron microscopy confirmed the relatively mature erythroblastic phenotype of the cells. In addition, ERY-1 cell line expressed beta-globin mRNA and a non-phosphorylable form of the erythropoietin receptor, even in presence of erythropoietin. Of note, the proliferation of ERY-1 cells was inhibited by TGFbeta1 or STI-571 (Gleevec), without significant induction of further differentiation. In conclusion, ERY-1 is a new growth factor-independent human erythroleukemic cell line with a relatively mature phenotype that may be useful to study the molecular events involved in erythroblastic differentiation.
Unité CNRS UMR 8147, Faculté de Pharmacie et Hôpital Necker 4, Avenue de l'Observatoire 75006, Paris, France.
Antoine
A
Ribadeau Dumas
Nadine Ben
NB
Hamouda
Laurence
L
Leriche
Marie-Claude
MC
Piffaut
Patrick
P
Bonnemye
René Lai
RL
Kuen
Viviane
V
Tricottet
Hélène
H
Merle-Beral
Florence
F
N'Guyen Khac
Michel
M
Arock
D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D001549:Benzamides; D045744:Cell Line, Tumor; D002898:Chromosomes, Human, Pair 8; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D020440:Gene Duplication; D005914:Globins / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D010641:Phenotype; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D017467:Receptors, Erythropoietin / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D053773:Transforming Growth Factor beta1; D014178:Translocation, Genetic; D014314:Trisomy
D015703:Antigens, CD; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D017467:Receptors, Erythropoietin; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000068877:Imatinib Mesylate; D005914:Globins; D016044:Fusion Proteins, bcr-abl